Trial reportJournal of proteome research2015
LC-MS metabolomics of psoriasis patients reveals disease severity-dependent increases in circulating amino acids that are ameliorated by anti-TNFα treatment.
Trial report in Journal of proteome research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- Cutaneous and systemic improvements in psoriasis patients after different biologic treatments in a real-world longitudinal prospective study.Scientific reports · 2025Trial
- Phenylalanine exacerbates psoriasiform inflammation through NF‑κB‑mediated dendritic cell activation and Th17 polarization.International journal of molecular medicine · 2026Article
- Multi‑omics and their integration in psoriasis research (Review).Molecular medicine reports · 2026Review
- Divergent immunometabolic reprogramming in psoriasis and atopic dermatitis: a tale of two inflammatory skin diseases.Frontiers in immunology · 2026Review
- Nail Amino Acid and Trace Element Profiles and Their Association with Clinical Severity in Nail Psoriasis.Clinical, cosmetic and investigational dermatology · 2026Article
- The metabolomic profile of psoriatic arthritis patients unveils the unbalance of disease-related molecules and pathways.Scientific reports · 2025Article
- Role of SLC16A10 in Psoriasis Through the Regulation of Arachidonic Acid Metabolism in Keratinocytes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- An epidermal serine sensing system for skin healthcare.Nature communications · 2025Article
- Low Serum Methylglyoxal Levels Correlate with Psoriasis Severity and Inflammatory Response Indices.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025Article
- Metabolic profiling of psoriasis vulgaris and palmoplantar pustulosis.Experimental dermatology · 2024Article
- Plasma metabolomic profiling reveals a novel circulating biomarker signature in chronic pruritus of unknown origin.Scientific reports · 2024Article
- FBP1 orchestrates keratinocyte proliferation/differentiation and suppresses psoriasis through metabolic control of histone acetylation.Cell death & disease · 2024Article
- The new era of immune skin diseases: Exploring advances in basic research and clinical translations.Journal of translational autoimmunity · 2024Article
- Development and trends in metabolomics studies in psoriasis: A bibliometric analysis of related research from 2011 to 2024.Heliyon · 2024Article
- Energy competition remodels the metabolic glucose landscape of psoriatic epidermal cells.Theranostics · 2024Article
- Signaling pathways and targeted therapies for psoriasis.Signal transduction and targeted therapy · 2023Review
- Identifying Serum Metabolomic Markers Associated with Skin Disease Activity in Patients with Psoriatic Arthritis.International journal of molecular sciences · 2023Article
- Metabolomics analysis reveals cytotoxic effects of ouabain towards psoriatic keratinocytes via impairment of glutathione metabolism.Molecular genetics and genomics : MGG · 2023Article
- Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine.International journal of molecular sciences · 2023Review
- A Novel E3 Probiotics Formula Restored Gut Dysbiosis and Remodelled Gut Microbial Network and Microbiome Dysbiosis Index (MDI) in Southern Chinese Adult Psoriasis Patients.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Psoriasis is an immune-mediated highly heterogeneous skin disease in which genetic as well as environmental factors play important roles. In spite of the local manifestations of the disease, psoriasis may progress to affect organs deeper than the skin. These effects are documented by epidemiological studies, but they are not yet mechanistically understood. In order to provide insight into the systemic effects of psoriasis, we performed a nontargeted high-resolution LC-MS metabolomics analysis to measure plasma metabolites from individuals with mild or severe psoriasis as well as healthy controls. Additionally, the effects of the anti-TNFα drug Etanercept on metabolic profiles were investigated in patients with severe psoriasis. Our analyses identified significant psoriasis-associated perturbations in three metabolic pathways: (1) arginine and proline, (2) glycine, serine and threonine, and (3) alanine, aspartate, and glutamate. Etanercept treatment reversed the majority of psoriasis-associated trends in circulating metabolites, shifting the metabolic phenotypes of severe psoriasis toward that of healthy controls. Circulating metabolite levels pre- and post-Etanercept treatment correlated with psoriasis area and severity index (PASI) clinical scoring (R(2) = 0.80; p < 0.0001). Although the responsible mechanism(s) are unclear, these results suggest that psoriasis severity-associated metabolic perturbations may stem from increased demand for collagen synthesis and keratinocyte hyperproliferation or potentially the incidence of cachexia. Data suggest that levels of circulating amino acids are useful for monitoring both the severity of disease as well as therapeutic response to anti-TNFα treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.